KRAS degradation averts PDAC chemoresistance

被引：0
|
作者：
Leonhardt, Laura [1 ,2 ,3 ]
Hebrok, Matthias [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Tech Univ Munich, TUM Sch Med & Hlth, Munich, Germany
[2] Tech Univ Munich, Ctr Organoid Syst, Garching, Germany
[3] Inst Diabet & Organoid Technol, Helmholtz Diabet Ctr, Helmholtz Zentrum Munchen, Neuherberg, Germany
[4] Tech Univ Munich, Munich Inst Biomed Engn MIBE, Munich, Germany
[5] German Ctr Diabet Res DZD, Neuherberg, Germany
[6] Univ Calif San Francisco, Diabet Ctr, Dept Med, San Francisco, CA 94143 USA
来源：
NATURE CANCER | 2024年 / 5卷 / 03期
关键词：
D O I：
10.1038/s43018-023-00708-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.
引用
收藏
页码：375 / 377
页数：3
相关论文
共 50 条
  • [21] JNK inhibition reprograms the tumor-immune-microenvironment to overcome chemoresistance in PDAC
    Box, Edmond W., III
    Singh, Samara
    Garrido, Vanessa Tonin
    Mehra, Siddharth
    Amirian, Haleh
    Dickey, Erin M.
    Martos, Mary
    Nagathihalli, Nagaraj
    Datta, Jash
    Merchant, Nipun
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S61 - S62
  • [22] Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2
    Tao, Shasha
    Wang, Shue
    Moghaddam, Seyed Javad
    Ooi, Aikseng
    Chapman, Eli
    Wong, Pak K.
    Zhang, Donna D.
    CANCER RESEARCH, 2014, 74 (24) : 7430 - 7441
  • [23] KRAS inhibition targets and depends on pro-oncogenic HuR in PDAC cells
    Halamish, Hen
    Bush, Michaela
    Smith, Alexander
    Sears, Rosalie
    Brody, Jonathan
    CANCER RESEARCH, 2024, 84 (02)
  • [24] Therapeutic benefit of targeting ERK in mutant KRAS in pancreatic ductal adenocarcinoma (PDAC)
    Hayes, Tikvah K.
    Neel, Nicole F.
    Chenard, Melissa
    Yeh, Jen Jen
    Samatar, Ahmed
    Der, Channing J.
    CANCER RESEARCH, 2013, 73
  • [25] Novel strategy to make KRAS targeted therapies more effective for PDAC treatment
    Bulnes, Ana I.
    Garcia, Orlando
    Shaji, Poornima
    Holla, Swathi
    Dan, Nirnoy
    Dhasmana, Anupam
    Malik, Shabnam
    Yallapu, Murali
    Behrman, Stephen
    Chauhan, Subhash
    Khan, Sheema S.
    CANCER RESEARCH, 2023, 83 (07)
  • [26] Defining the Role of Mitochondrial Dynamics in Regulating PDAC Cell Sensitivity to KRAS and ERK Inhibition
    Amparo, Amber
    Drizyte-Miller, Kristina
    Gates, Claire
    Cox, Adrienne D.
    Bryant, Kirsten L.
    Der, Channing J.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
  • [27] Oncogenic KRAS relies on ß1 integrin expression to drive pancreatic neoplasia and PDAC development
    Muschler, John L.
    Huang, Ge
    Smith, Alexander C.
    Sears, Rosalie C.
    CANCER RESEARCH, 2024, 84 (02)
  • [28] Pilot study of plasma KRAS as a prognostic biomarker in localized pancreas ductal adenocarcinoma (PDAC).
    Krantz, Benjamin A.
    Gedvilaite, Erika
    Chou, Joanne F.
    Capanu, Marinela
    You, Daoqi
    Yu, Kenneth H.
    Varghese, Anna M.
    Iacobuzio-Donahue, Christine A.
    Kelsen, David Paul
    Tsui, Dana
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [29] Syndecan-1 is required for oncogenic Kras-driven PDAC tumorigenesis and maintenance
    Yao, Wantong
    Wang, Wei
    Taguchi, Ayumu
    Kapoor, Avnish
    Momin, Amin
    Jiang, Hong
    Rose, Johnathon
    Celiktas, Muge
    Deem, Angela
    Hanash, Samir
    DePinho, Ronald
    Ying, Haoqiang
    Draetta, Giulio
    CANCER RESEARCH, 2015, 75
  • [30] Characterization of PDAC and IPMN based on RNA expression analyses and KRAS/GNAS mutation status
    Illge, F.
    Offenborn, S.
    Jakobs, H.
    Falk, M.
    Kirfel, J.
    Tiemann, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 12 - 12
12345